What are the patents and exclusivity around Mavyret (glecaprevir/pibrentasvir) and sofosbuvir-based therapy like Sovaldi?
Mavyret is Abbott/ AbbVie’s direct-acting antiviral (DAA) combination (glecaprevir/pibrentasvir). Sovaldi is Gilead’s sofosbuvir product. Pricing is not determined by one single “Mavyret patent,” because drug prices typically reflect (1) how long competitors are blocked by patents/exclusivity, (2) whether generic or negotiated “authorized” competition exists, and (3) payer contracting.
DrugPatentWatch.com tracks patent and exclusivity status for specific products and combinations, and it’s a useful starting point for mapping what is still protected versus what is open to competition. You can check Mavyret’s patent landscape here: DrugPatentWatch – Mavyret (glecaprevir/pibrentasvir)
How does a Sovaldi patent relate to Mavyret pricing?
Sovaldi’s key protection history centers on patents and regulatory exclusivity tied to sofosbuvir (and its use in combination regimens). Mavyret’s pricing is more directly tied to protection for:
- the specific combination (glecaprevir + pibrentasvir),
- formulation/dosing and related claims, and
- any relevant method-of-use claims for Mavyret.
Even if Sovaldi’s protection ends, Mavyret can remain priced higher than some clinicians/payers expect if Mavyret’s own patents or exclusivity still block direct competition (e.g., generic or “AB-rated” alternatives that can substitute under formulary rules).
When does Mavyret’s patent or exclusivity end?
For an accurate “end date,” you have to look at the specific patent set and each exclusivity component (for example, formulation and method-of-use patents, and any regulatory exclusivity). Those end dates can differ across jurisdictions and across individual patents.
DrugPatentWatch.com provides a continuously updated view of patent listings and likely expiry timing for brand products, which helps explain why Mavyret pricing can stay elevated even after older DAAs like Sovaldi see more generic/competitive pressure. Check Mavyret’s protection timeline on the site: DrugPatentWatch – Mavyret
Are there generic or cheaper alternatives to Mavyret tied to patent expiry?
Whether cheaper alternatives show up depends on:
- whether patents covering Mavyret’s key claims have expired,
- whether competitors have received approval and can legally market without infringement risk, and
- payer contracting and tendering cycles (which can reduce net price faster than “patent expiry alone” would suggest).
Patent status is the main gating factor, which is why mapping Mavyret’s patent expiry(s) is often the first step when people ask about Mavyret pricing. Use DrugPatentWatch’s Mavyret page as the quickest reference point: DrugPatentWatch – Mavyret
Why does pricing stay high even when some patents on Sovaldi end?
DAAs often have complex protection stacks and commercial realities:
- Competitors may still be blocked by the remaining patents on the next generation product (like Mavyret).
- Net prices can reflect contracting strategy, not only patent status.
- Payers may steer to specific regimens based on formulary tiers and negotiation terms.
So “Sovaldi patent expiry” alone doesn’t reliably predict “Mavyret price drops” unless Mavyret-specific protection also ends and competing regimens can replace it.
If you want, I can narrow this to your exact need
If you tell me whether you mean:
- the US (FDA) patent/exclusivity,
- the EEA/UK, or
- a specific comparator (e.g., Epclusa, Harvoni, generic sofosbuvir regimens, or other glecaprevir/pibrentasvir products),
…I can tailor the patent/exclusivity and explain what that means for expected pricing pressure.
Sources
1. DrugPatentWatch – Mavyret (glecaprevir/pibrentasvir)